How to Pull the Right Regulatory Levers: Interview with Linear Health Sciences Founder and President Daniel Clark

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded26 Oct 2022

Publisherfeeds.transistor.fm ↗

Handlerec:13866324

Show notes

In this episode of Medsider Radio, we sat down with Dan Clark, President of Linear Health Sciences. Dan Clark started his career in the private sector at Parker Hannifin, a Fortune 200 organization that he calls “the largest company you’ve never heard of.” After experiencing the medtech innovation cycle many times over, he was eager to innovate himself. In 2015, Dan teamed up with Dr. Ryan Dennis to start Linear Health Sciences, a medtech company that created the Orchid, a device designed to mitigate unwanted or accidental IV dislodgement.In this interview, Dan explains when and how Linear raised capital, how it has navigated complex regulatory pathways, and why you need to be your own worst enemy as an innovator.Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Dan if you'd rather read it instead.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.